At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 744 enrolled
Drug / intervention
Tazarotene foam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Tazarotene foam and Vehicle Foam for Acne Vulgaris. Completed, enrolled 744 participants across 22 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedNov 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedNov 20, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.6 years ago
Interventions
Tazarotene foamdrug
Tazarotene foam once a day application to the face
Vehicle Foamdrug
Vehicle Foam once a day application to the face